-- First targeted therapy approved in Canada for patients four years and older living with acquired hypothalamic obesity (HO) -- -- First targeted therapy approved in Canada for patients four years and older living with acquired hypothalamic obesity (HO)
Globe Newswire
Original source
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Envisagenics today announced a multi-year research collaboration and option agreement with Boehringer Ingelheim to validate selected tumor-specific targets for the development of first-in-class precision therapies for people living with solid tumors. Envisagenics has pioneered an artificial intelligence (AI)-powered approach that is transforming alternative RNA splicing into a new frontier for drug discovery.
Adventist Health Bakersfield is first in Kern County to use Noah Medical's next-generation, robotic-assisted bronchoscopy for earlier lung cancer diagnosis
AUSTIN, Texas, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing simufilam for the treatment of Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Company's investigational new drug (IND) application, enabling Filana to initiate a planned Phase 2a proof-of-concept study in patients aged 12 to 55 with TSC-related epilepsy. Patient screening is expected to begin by the first quarter of 2027.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from the Phase 2b AMPLIFIED study of inaxaplin in people with APOL1-mediated kidney disease (AMKD) and modest proteinuria and in people with AMKD and type 2 diabetes.
Headlines and briefs on this site are for information only. Always verify details on the original source or live status page.
Read Disclaimer